LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

    Schmoll, H-J / Jordan, K / Huddart, R / Laguna, M P / Horwich, A / Fizazi, K / Kataja, V

    Annals of oncology : official journal of the European Society for Medical Oncology

    2009  Volume 20 Suppl 4, Page(s) 89–96

    MeSH term(s) Europe/epidemiology ; Follow-Up Studies ; Health Planning Guidelines ; Humans ; Male ; Seminoma/diagnosis ; Seminoma/therapy ; Societies, Medical/standards ; Testicular Neoplasms/diagnosis ; Testicular Neoplasms/therapy ; Treatment Outcome
    Language English
    Publishing date 2009-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdp139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.

    Oldenburg, J / Aparicio, J / Beyer, J / Cohn-Cedermark, G / Cullen, M / Gilligan, T / De Giorgi, U / De Santis, M / de Wit, R / Fosså, S D / Germà-Lluch, J R / Gillessen, S / Haugnes, H S / Honecker, F / Horwich, A / Lorch, A / Ondruš, D / Rosti, G / Stephenson, A J /
    Tandstad, T

    Annals of oncology : official journal of the European Society for Medical Oncology

    2014  Volume 26, Issue 5, Page(s) 833–838

    Abstract: ... Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi125-vi132; de Wit R, Fizazi ... Oldenburg J, Fossa SD, Nuver J et al. Testicular seminoma and non-seminoma: ESMO ... of surveillance and adjuvant treatment is a prerequisite for informed consent by the patient. In a clinical ...

    Abstract Testicular cancer (TC) is the most common neoplasm in males aged 15-40 years. The majority of patients have no evidence of metastases at diagnosis and thus have clinical stage I (CSI) disease [Oldenburg J, Fossa SD, Nuver J et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi125-vi132; de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006; 24: 5482-5492.]. Management of CSI TC is controversial and options include surveillance and active treatment. Different forms of adjuvant therapy exist, including either one or two cycles of carboplatin chemotherapy or radiotherapy for seminoma and either one or two cycles of cisplatin-based chemotherapy or retroperitoneal lymph node dissection for non-seminoma. Long-term disease-specific survival is ∼99% with any of these approaches, including surveillance. While surveillance allows most patients to avoid additional treatment, adjuvant therapy markedly lowers the relapse rate. Weighing the net benefits of surveillance against those of adjuvant treatment depends on prioritizing competing aims such as avoiding unnecessary treatment, avoiding more burdensome treatment with salvage chemotherapy and minimizing the anxiety, stress and life disruption associated with relapse. Unbiased information about the advantages and disadvantages of surveillance and adjuvant treatment is a prerequisite for informed consent by the patient. In a clinical scenario like CSI TC, where different disease-management options produce indistinguishable long-term survival rates, patient values, priorities and preferences should be taken into account. In this review, we provide an overview about risk factors for relapse, potential benefits and harms of adjuvant chemotherapy and active surveillance and a rationale for involving patients in individualized decision making about their treatment rather than adopting a uniform recommendation for all.
    MeSH term(s) Adolescent ; Adult ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Chemotherapy, Adjuvant ; Choice Behavior ; Decision Support Techniques ; Disease Progression ; Humans ; Male ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Germ Cell and Embryonal/pathology ; Neoplasms, Germ Cell and Embryonal/therapy ; Orchiectomy/adverse effects ; Patient Participation ; Patient Selection ; Personal Autonomy ; Predictive Value of Tests ; Radiotherapy, Adjuvant ; Risk Factors ; Seminoma/pathology ; Seminoma/therapy ; Testicular Neoplasms/pathology ; Testicular Neoplasms/therapy ; Time Factors ; Treatment Outcome ; Watchful Waiting ; Young Adult
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2014-11-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdu514
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top